CN Patent

CN112007024A — 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2020-12-01 · 5y expired

What this patent protects

本申请涉及艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途。具体而言，本申请涉及一种艾瑞昔布与曲马多或其药用盐联合在制备治疗疼痛的药物中的用途。具体的疼痛可选自急性疼痛、慢性疼痛、神经病性疼痛、伤害感受性疼痛、轻微及重度至中度疼痛、痛觉过敏、与中枢敏感化有关的疼痛、异常性疼痛或癌症疼痛，包括糖尿病性神经病变及骨关节炎；以及包括类风湿性关节炎、强直性脊柱炎、坐骨神经痛及冻结肩。

USPTO Abstract

本申请涉及艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途。具体而言，本申请涉及一种艾瑞昔布与曲马多或其药用盐联合在制备治疗疼痛的药物中的用途。具体的疼痛可选自急性疼痛、慢性疼痛、神经病性疼痛、伤害感受性疼痛、轻微及重度至中度疼痛、痛觉过敏、与中枢敏感化有关的疼痛、异常性疼痛或癌症疼痛，包括糖尿病性神经病变及骨关节炎；以及包括类风湿性关节炎、强直性脊柱炎、坐骨神经痛及冻结肩。

Drugs covered by this patent

Patent Metadata

Patent number
CN112007024A
Jurisdiction
CN
Classification
—
Expires
2020-12-01
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Hengrui Medicine Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.